Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy

  • Authors:
    • Keisuke Ihara
    • Satoru Yamaguchi
    • Nozomi Ueno
    • Yukiko Tani
    • Yosuke Shida
    • Hideo Ogata
    • Yasushi Domeki
    • Kentaro Okamoto
    • Masanobu Nakajima
    • Kinro Sasaki
    • Takashi Tsuchioka
    • Hiroyuki Mitomi
    • Hiroyuki Kato
  • View Affiliations

  • Published online on: December 16, 2015     https://doi.org/10.3892/or.2015.4488
  • Pages: 1349-1355
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

DNA intrastrand cross-linking agents such as oxaliplatin induce DNA double-strand breaks (DSBs) during DNA repair and replication. In the present study, we hypothesized that DNA intrastrand cross-linking agents may significantly benefit colorectal cancer patients with deficiencies in DSB repair. Seventy-eight patients with metastatic or recurrent colorectal cancer who had measurable target lesions and who underwent resection for primary colorectal cancer in our institution between April 2007 and March 2013 were included in the present study. The median age was 64.5 years, and the cohort consisted of 49 males and 29 females. The median progression-free survival (PFS) was 10.9 months. The expression of DSB repair proteins such as RAD51 and MRE11 was investigated by immunohistochemistry, and associations between RAD51 and MRE11 expression and clinicopathological factors or chemotherapeutic effect were assessed. MRE11-negative cases and RAD51-negative cases achieved significantly better tumor reduction compared with cases with positive expression. Cases with negative expression of both proteins or negative expression of either protein had significantly longer PFS than cases with positive expression for both proteins. In conclusion, DSB repair protein expression-negative colorectal cancer cases may be more highly sensitive to chemotherapy, and thus DSB repair protein expression may be a useful prognostic indicator for colorectal cancer patients.
View Figures
View References

Related Articles

Journal Cover

March-2016
Volume 35 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ihara K, Yamaguchi S, Ueno N, Tani Y, Shida Y, Ogata H, Domeki Y, Okamoto K, Nakajima M, Sasaki K, Sasaki K, et al: Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Oncol Rep 35: 1349-1355, 2016
APA
Ihara, K., Yamaguchi, S., Ueno, N., Tani, Y., Shida, Y., Ogata, H. ... Kato, H. (2016). Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Oncology Reports, 35, 1349-1355. https://doi.org/10.3892/or.2015.4488
MLA
Ihara, K., Yamaguchi, S., Ueno, N., Tani, Y., Shida, Y., Ogata, H., Domeki, Y., Okamoto, K., Nakajima, M., Sasaki, K., Tsuchioka, T., Mitomi, H., Kato, H."Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy". Oncology Reports 35.3 (2016): 1349-1355.
Chicago
Ihara, K., Yamaguchi, S., Ueno, N., Tani, Y., Shida, Y., Ogata, H., Domeki, Y., Okamoto, K., Nakajima, M., Sasaki, K., Tsuchioka, T., Mitomi, H., Kato, H."Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy". Oncology Reports 35, no. 3 (2016): 1349-1355. https://doi.org/10.3892/or.2015.4488